https://doi.org/10.55788/c81bfc41
The effects of public health interventions in response to the COVID-19 pandemic on outcomes in PD patients are unknown. A study was conducted to determine the impact of those interventions on mood, movement, and quality of life of PD patients [1]. More specifically, Mr Ari Vandersluis (Heritage College of Osteopathic Medicine, OH, USA) and colleagues focused on possible consequences of disrupting lifestyle behaviours known to favour PD outcomes (such as exercise and social interaction frequencies), as well as the introduction of telemedicine for outpatient visits.
Both before and after the onset of COVID-19 public health interventions, comprehensive clinical assessments were carried out in 150 PD patients. The first visit was in-person, the second visit by telephone call. Results of the second, post-COVID visit showed an increase in the Hoehn and Yahr scale, a scale to rate PD progression, compared with the first, pre-COVID visit (n=122; 2.02 vs 1.86; P=0.006) Several non-movement PD symptoms were found to have worsened during the subsequent visit, including activities of daily living status, exercise frequency, and sleep disturbance frequency. There was generally no worsening of movement symptoms, including bradykinesia, rigidity, resting tremor, gait abnormality, and falls. The need for levodopa did not increase.
- Vandersluis A, et al. Evaluating Outcomes in Parkinsonâs Disease Patients Following COVID-19 Interventions. S16.007, AAN 2022, 02â07 April, Seattle, USA.
Copyright ©2022 Medicom Medical Publishers
Posted on
Previous Article
« Intravenous thrombolysis after ischaemic stroke: When in doubt, leave it out? Next Article
IPX203 versus immediate release carbidopa-levodopa »
« Intravenous thrombolysis after ischaemic stroke: When in doubt, leave it out? Next Article
IPX203 versus immediate release carbidopa-levodopa »
Table of Contents: AAN 2022
Featured articles
Letter from the Editor
Interview with Prof. Natalia Rost
Alzheimerâs Disease and Other Dementias
Targeting senescent cells to treat age-related diseases
Cardiorespiratory fitness protects against dementia
Safety and effects of bosutinib in Lewy body dementia
Epilepsy
âWomen with epilepsy should be encouraged to breastfeedâ
Fenfluramine: possible new treatment for Lennox-Gastaut syndrome
Laser interstitial thermal therapy for refractory epilepsy
Migraine
Migraine may be an important obstetric risk factor
Intranasal zavegepant safe and well tolerated in healthy adults
Telemedicine during COVID-19 pandemic highly appreciated
Multiple Sclerosis
Ublituximab versus teriflunomide in relapsing MS patients
Ketogenic diet may improve disability and quality of life
Favourable additional safety data for ofatumumab
Predicting new T2 lesions using a machine learning algorithm
Evobrutinib reduces volume of slowly expanding lesions
Sustained long-term efficacy and safety of satralizumab in NMOSD
Muscle and Neuro-Muscular Disorders
Ravulizumab in patients with generalised myasthenia gravis
Gene therapy effective in older patients with spinal muscular atrophy
Losmapimod for facioscapulohumeral muscular dystrophy
SRP-9001 for treating patients with Duchenne muscular dystrophy
Cerebrovascular Disease and Stroke
Intravenous thrombolysis after ischaemic stroke: When in doubt, leave it out?
Better outcomes with mechanical thrombectomy in elderly stroke patients
Plasma NfL levels associated with cardiovascular risk
Non-invasive vagus nerve stimulation for acute stroke
Parkinsonâs Disease
Prasinezumab in Parkinsonâs disease: delayed-start analysis of PASADENA trial
IPX203 versus immediate release carbidopa-levodopa
Impact of COVID-19 public health interventions
COVID-19
Cognitive, EEG, and MRI features in COVID-19 survivors
Neurological manifestations of COVID-19 worsen prognosis
New evidence for biological basis of âCOVID-19 brain fogâ
Related Articles
September 17, 2021
Vaccination feasible in people with psoriatic disease
June 12, 2023
Mitochondrial DNA levels predict COVID-19 severity
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com